United States biotechnology company Moderna announced it was developing a SARS-CoV-2 vaccine in January 2020. However, scientists at National Institutes of Health conceived the original idea according to CBC News, and now they are working together. Moderna coronavirus testing is ready for the final phase after successful preliminary trials. No matter how you slice it, it’s good news says Anthony Fauci of National Institute of Allergy and Infectious Diseases.
A Short Recap How We Got to This Landmark
The Moderna coronavirus test now ready for the final hurdle uses a ‘messenger’ RNA compound. Then this message prevents the SARS-CoV-2 virus forming a spike protein. And moreover it teaches the host body to respond and resist it. This is a novel approach compared to injecting actual viruses according to Cleveland.Com.
The results of the first trial involving 45 human volunteers rolled out on July 14, 2020. CBS News confirms the subjects developed the same neutralizing antibodies as people who survived the COVID-19 disease. This is the vital building block we need to move forward, says lead researcher Lisa Jackson.
The Final Stages Lying Ahead for the Moderna Coronavirus Test
The second and optimistically final trials for the vaccine will begin soon. After that, Moderna president Stephen Hoge hopes to start distributing the vaccine by late 2020 in two doses one month apart.
The subjects in the trial exhibited typical Covid-19 symptoms. Those receiving the lower dose experienced fatigue, headache, chills, fever, and pain at the injection site the day after. However, those on the higher dose experienced severe symptoms leading to researchers abandoning that option.
There are a number of other experimental vaccines currently under test. Anthony Fauci sees this as a positive sign. That’s because the final test for the Moderna coronavirus vaccine is not a race for a single winner, he says. We need vaccines for the world, not just for our country he told CBS News.
Related
A Vaccine to Help Our Immune System Fight
Oxford COVID-19 Trials Enter Stage 3
Preview Image: Accelerated Vaccine Development
